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Abstract: Objective: In 2013, the American College of Rheumatology (ACR) participated in the Choosing Wisely 
campaign and devised a recommendation to avoid testing antinuclear antibody (ANA) subserologies without a positive 
ANA and clinical suspicion of disease. The goals of our study were to describe ANA and subserology ordering practices 
and predictors of ordering concurrent ANA and subserologies in a safety-net hospital. 
Methods: We identified ANA and subserologies (dsDNA, Sm, RNP, SSA, SSB, Scl-70 and centromere) completed at 
Denver Health between 1/1/2005 and 12/31/2011. Variables included demographics, primary insurance, service, and 
setting from which the test was ordered. We performed multivariable logistic regression to determine predictors of 
concurrent ordering of ANA and subserologies. 
Results: During seven years, 3221 ANA were performed in 2771 individuals and 211 (6.6%) were performed concurrently 
with at least one subserology. The most common concurrent subserologies were dsDNA (21.8%), SSA (20.8%), and SSB 
(19.7%). In the multivariable logistic analysis, significant predictors of concurrent ANA and subserologies were the labs 
being ordered from subspecialty care (OR 8.12, 95% CI 5.27-12.50, p-value <0.0001) or from urgent/inpatient care (OR 
3.86, 95% CI 1.78-8.38, p-value 0.001). A significant predictor of decreased odds was male gender (OR 0.32, 95% CI 
0.21-0.49, p-value <0.0001). Five individuals (2.2% of the negative ANA with subserologies ordered) had a negative 
ANA but positive subserologies. 
Conclusion: Of 3221 ANA, 6.6% were performed concurrently with subserologies, and subspecialists were more likely to 
order concurrent tests. A negative ANA predicted negative subserologies with rare exceptions, which validates the ACR’s 
recommendations. 
Keywords: Antinuclear antibody (ANA), choosing wisely, ordering practices, quality of care, quality indicators, resource 
management. 
INTRODUCTION 
 In 2013, Yazdany et al. [1] published the Choosing 
Wisely Top 5 recommendations for the American College of 
Rheumatology (ACR). These recommendations were in 
response to the American Board of Internal Medicine 
Foundation’s Choosing Wisely campaign, which encouraged 
medical professional societies to propose a list of five tests, 
treatments, or services that are commonly used, but the 
usefulness of which should be reevaluated by clinicians and 
patients. One of the ACR’s Top 5 recommendations was  
“Do not test antinuclear antibody (ANA) subserologies 
without a positive ANA and clinical suspicion of immune-
mediated disease” [1]. This recommendation was made in 
the setting of previous work, which indicated that with the  
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use of the HEp-2 cell line, ANA tests are very sensitive (93-
99%) [2-4] for the diagnosis of systemic lupus erythematosus 
(SLE). Historically, ANA tests using non-human substrates 
can lose the ability to detect SSA, thus producing false 
negative results [5-8]. However, the human-derived HEp-2 
cell line, which can be transfected with the SSA antigen [9], 
is thought to be more sensitive than non-human substrates, 
although not all laboratories utilize transfected cells. 
 In 2000, guidelines issued by the American College of 
Rheumatology along with members of the College of 
American Pathologists stated “using HEp-2 cells as a 
substrate has virtually eliminated false-negative ANA 
results. Aside from rare cases, further autoantibody testing, if 
a patient has a negative ANA finding, is not indicated” [10]. 
Similarly, in 2002, the Italian Society of Laboratory 
Medicine [11] developed guidelines for laboratory testing 
and stated that “in the case of a negative ANA… [further] 
antinuclear specific antibody [subserology] testing is only 
indicated when a patient has clear signs of an autoimmune 
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rheumatic disease”. Thus, the ANA item in the ACR’s Top 5 
list asserts that: “Tests for ANA subserologies (including 
antibodies to double-stranded DNA, Sm, RNP, SSA, SSB, 
Scl-70, and centromere) are usually negative if the ANA is 
negative. Exceptions include anti-Jo-1, which can be positive 
in some forms of myositis, or occasionally, anti-SSA in the 
setting of lupus or Sjogren’s syndrome. Broad testing of 
autoantibodies should be avoided; instead, the choice of 
autoantibodies should be guided by the specific disease 
under consideration” [1].   
 These recommendations have been supported by some 
small-scale studies. In one study, ANA subserologies were 
reviewed in 153 individuals who were found to have a 
negative ANA screen, and no positive subserologies were 
detected [12]. In another study, ANA subserologies (SSA, 
SSB, Sm, RNP) were examined in 468 patients with a 
negative ANA. Three patients were identified who were 
consistently ANA negative, but had at least one positive 
subserology (0.64%) [13]. 
 Complicating these recommendations, however, is each 
individual laboratory’s choice of ANA testing technique. 
Frequently, laboratories choose enzyme-linked 
immunosorbent assays (ELISA) as an initial screen, which is 
then verified by indirect fluorescent assay (IFA) using the 
HEp-2 cells. This practice is often utilized clinically due to 
the labor-intensive nature of the IFA. One recent publication 
showed that one particular laboratory’s ELISA had a 
negative predictive value (NPV) of 0.92 in SLE [14]. While 
a NPV of 0.92 is quite good, it does leave room for some 
individuals who might have a negative ELISA ANA but a 
positive IFA ANA. 
 Recently, some laboratories have offered an “arthritis” 
panel, which provides an opportunity to test a number of 
subserologies at once, including ANA and ANA 
subserologies. Alternatively, some laboratories offer ANA 
reflex testing, which cancels the ANA subserologies if the 
ANA is negative. While ANA reflex testing likely saves 
money compared to arthritis panels, not all laboratories offer 
reflex panels, and the reflex panels are not symptom-guided. 
This Top 5 item specifically argues against the use of such 
panels as they may be used for non-specific symptoms and 
may result in unnecessary testing and false positive tests. To 
our knowledge, ordering patterns of ANA and subserologies 
have not been recently investigated. 
 To address this gap in knowledge, we examined the 
ordering patterns for ANA and ANA subserologies in 
Denver Health, a large safety-net hospital in Denver, 
Colorado. Denver Health is in an interesting position to 
examine this recommendation, as each subserology must be 
ordered individually, as opposed to a reflex or arthritis panel. 
We felt that this particular institutional requirement offered a 
unique window into the practice patterns of general and 
subspecialty clinicians. Our specific goals were to: 1) 
evaluate the ordering practices of our health system, focusing 
on concurrent ANA and subserology orders; 2) investigate 
predictors of concurrent ordering of ANA and subserologies; 
and 3) report the outcomes in which a patient was found to 
be ANA negative but have a positive subserology. 
 
MATERIALS AND METHODS 
Study Population and Variables 
 We identified all ANA and subserologies (dsDNA, Sm, 
RNP, SSA, SSB, Scl-70, and centromere) that were 
completed at Denver Health between January 1, 2005 and 
December 31, 2011 via query of the electronic medical 
record. We identified additional demographic variables, 
including: age at the time of antibody testing; gender; the 
setting from which the test was ordered (outpatient, lab draw 
alone, emergency or urgent care, or inpatient); the service 
that ordered the test (primary care, specialty service, or other 
[emergency/urgent care or inpatient care]); race/ethnicity 
(Hispanic, Caucasian, African American, other/unknown); 
and primary payer (medically indigent, Medicaid, Medicare, 
commercial insurance, self-pay, or other/unknown). 
 ANA ordered at Denver Health are sent to a national 
reference laboratory (Quest or ARUP) where specimens are 
screened using an enzyme-linked immunosorbent assay 
(ELISA) method, detecting IgG-specific antibodies. ELISA 
screen results that are reported as "detected,” based on 
optical density, are followed by indirect fluorescent assay 
(IFA) using HEp-2 cells with an IgG-specific conjugate. 
Reflexive IFA testing is reported as a titer with a reference 
range of <1:40. ANA subserologies are performed using 
multiplex bead technology with reference intervals 
established by the manufacturer. 
 We performed chart reviews for the individuals with 
consistently negative ANA, but at least one positive 
subserology. 
Statistical Analysis 
 We used descriptive statistics to analyze patterns of ANA 
testing, and utilized logistic regression to determine factors 
associated with concurrent ordering of ANA and at least one 
subserology test. We first examined variables as univariate 
analyses, and we included those variables in the 
multivariable analysis if the p-value was ≤ 0.2 in the 
univariate model. We considered variables to be significant 
in the multivariable model if the p-value was ≤ 0.05. All 
analyses were performed using STATA version 13.1 
(College Station, TX). 
Ethics 
 This project was submitted to the Colorado Multiple 
Institutional Review Board and was considered not human 
subject research, but rather a quality improvement project. 
RESULTS 
 During the seven-year time period, 3221 ANA were 
performed in 2771 individuals. In the majority of the 
individuals, (2400 or 86.6%), only one ANA was ordered. 
Two ANA were ordered in 305 individuals (11.0%), while 3 
were ordered in 55 individuals (2.0%), 4 in 9 individuals 
(0.3%), and 5 in 2 individuals (0.1%). 
 Of these 3221 ANA performed, 211 (6.6%) were done 
concurrently with at least one subserology (see Fig. 1). The 
most common concurrently ordered subserologies with an 
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ANA were dsDNA (21.8%), SSA (20.8%), SSB (19.7%), 
Sm (14.08%), RNP (13.03%), Scl-70 (7.22%), and  
 
 
centromere (3.35%). Of the 3010 ANA that were performed 
initially without subserologies, 579 (19.2%) were positive 
and 2431 (80.8%) were negative. Of the positive ANA that 
were performed without subserologies, 383 (66.1%) did not 
have subsequent subserologies performed, while 196 
(33.9%) did. Of the 2431 with a negative ANA and without 
concurrent subserologies ordered, 103 (4.2%) later had 
subserologies ordered. 
 The demographics by ANA performed are shown in 
Table 1. The mean patient age was 45.2 years (SD 14.4 
years). The majority of the ANA were performed in 
Hispanics (46%), and 89% of the ANA were performed in 
the outpatient setting. The majority of the ANA were ordered 
from the primary care service (59%), and the most common 
primary payer source was the medically indigent program 
(47%). 
 The results of the univariate and multivariable logistic 
regression models of predictors of concurrent ordering of an 
ANA and at least one subserology may be found in Table 2. 
In the multivariable logistic analysis, significant predictors 
of increased odds of ANA and subserologies being ordered 
concurrently were that the labs were ordered from 
subspecialty care (OR 8.12, 95% CI 5.27-12.50, p-value 
<0.0001) or from other care (OR 3.86, 95% CI 1.78-8.38, p-
value 0.001). A significant predictor of decreased odds of 
ANA and subserologies being ordered concurrently was 
male gender (OR 0.32, 95% CI 0.21-0.49, p-value <0.0001). 
 In total, there were five individuals (2.2% of the negative 
ANA with subserologies ordered) who had consistently 
negative ANA and positive subserologies. All five 
individuals were females, and ranging in age from 19-64 
years. Subserologies found to be positive in these individuals 
include SSA (2), Scl-70 (2), RNP (1), and dsDNA (1). Four 
out of the five were diagnosed with a mild form of SLE or  
other connective tissue disease, while one individual was felt 
to have a possible paraneoplastic process in the setting of 
concomitant non-small cell lung cancer. The details of these 
cases may be found in Appendix Table A1. 
Table 1. Demographics, by ANA ordered. 
 
Variable n= Mean, % SD 
Age, years (mean) 3,221 45.2 14.4 
Gender, male (%) 3,221 31.9   
Race/Ethnicity (%) 
  Hispanic 1,481 46.0   
  Caucasian 872 27.1   
  African American 677 21.0   
  Other/Unknown 191 5.9   
Setting in which ANA ordered (%) 
  Outpatient 2,381 89.4   
  Lab draw alone 226 8.5   
  Emergency 41 1.5   
  Inpatient 14 0.5   
Primary Payment Source (%) 
  Medically Indigent 1,354 46.5   
  Medicaid 741 25.4   
  Medicare 402 13.8   
  Commercial Insurance 336 11.5   
  Self-pay 48 1.7   
  Other/Unknown 33 1.1   
Service ordering ANA (%) 
  Primary care 1,704 58.5   
  Subspecialty care 1,010 34.7   
 
ANA: antinuclear antibody; Subser: subserology antibodies include SSA (Ro), SSB (La), Scl-70, dsDNA, Smith, centromere, and ribonucleoprotein (RNP). +: 
positive, as defined by the manufacturer; -: negative, as defined by the manufacturer 
Fig. (1). ANA and subserologies, with order of events. 
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  Other* 200 6.9   
*Other: includes emergency/urgent care, inpatient care. 
Variable included in the multivariable model if p-value <=0.2 in the univariate model; 
variable considered significant in the multivariable model if the p-value <=0.05. 
 
DISCUSSION 
 We found that when providers are given a choice (i.e. 
they must order laboratory examinations individually), only 
6.6% of ANA were ordered concurrently with a subserology. 
This indicates that providers at our institution typically do 
not overuse ANA subserology testing, but wait for the ANA 
to return before initiating subserology testing. This ordering 
pattern may be due to our hospital setting—a safety net 
hospital with a systematic effort toward efficient use of 
resources. The Top 5 recommendations acknowledge that 
clinical context dictates ordering patterns, and there likely 
are situations that warrant testing an ANA and subserologies 
at the same visit. These include but are not limited to: patient 
financial constraints with multiple co-pays; long travel times; 
and unclear reports of prior testing. The most likely 
subserologies to be ordered concurrently with an ANA were 
dsDNA, SSA, and SSB. While ordering SSA and possibly 
the SSB reflect possible pitfalls in ANA specificity [5-8], 
concurrent ordering of dsDNA does not. We propose this as 
an area for better education in our institution and a possible 
area of caution for other institutions. 
 Predictors of concurrent ordering of ANA and 
subserologies include that the labs were ordered from 
subspecialty care (OR 8.12, p-value <0.0001) or from other 
care, such as emergency/urgent care or inpatient care (OR  
3.86, p-value 0.001). We hypothesize that the increased 
concurrent ordering in subspecialty and other care may be 
driven by a high index of clinical suspicion for autoimmune 
disease and/or the long potential wait time to be seen in 
subspecialty clinics. That is, the clinicians in these clinics 
may want to maximize the laboratory information available 
when the patient is seen. While this approach may not be the 
most cost effective, it may be time-effective and decrease the 
time burden for patients. 
 A significant predictor of decreased odds of ANA and 
subserologies being ordered concurrently was male gender 
(OR 0.32, p-value <0.0001). Again, we suspect that this may 
be a reflection of clinicians’ clinical suspicion, as the 
majority of immune-mediated diseases affect females [15]. 
 Additionally, we found that only rarely were subserologies 
positive, when tested, in the setting of consistently negative 
Table 2. Univariate and multivariable logistic regression models of predictors of concurrent ordering of ANA and at least one 
subserology. 
 
Variable OR 95% CI p-Value OR 95% CI p-Value 
Age 1.00 0.99 1.01 0.655 1.01 0.99 1.02 0.457 
Sex, male  0.42 0.29 0.60 <0.0001 0.32 0.21 0.49 <0.0001 
Setting in which ANA ordered   
  
  
   
  
  Outpatient REF 
  
  REF 
  
  
  Lab Draw Alone 0.43 0.19 0.98 0.044 0.92 0.38 2.22 0.853 
  Emergency or Urgent Care 1.69 0.59 4.81 0.324 1.31 0.38 4.50 0.672 
  Inpatient 1.20 0.16 9.27 0.859 0.92 0.10 8.18 0.940 
Service that Ordered the ANA   
  
  
   
  
  Primary Care REF 
  
  REF 
  
  
  Subspecialty Care 6.36 4.41 9.18 <0.0001 8.12 5.27 12.50 <0.0001 
  Other* 4.22 2.37 7.53 <0.0001 3.86 1.78 8.38 0.001 
Race/Ethnicity   
  
  
   
  
  Hispanic REF 
  
  REF 
  
  
  Caucasian 1.16 0.82 1.63 0.409 0.96 0.63 1.45 0.839 
  African American 1.38 0.97 1.96 0.077 1.44 0.94 2.22 0.097 
  Other/Unknown 1.28 0.71 2.31 0.405 0.93 0.45 1.93 0.852 
Primary Payment Source   
  
  
   
  
  Medically Indigent REF 
  
  REF 
  
  
  Medicaid 1.05 0.71 1.55 0.802 0.93 0.59 1.44 0.735 
  Medicare 1.63 1.07 2.47 0.022 1.26 0.76 2.11 0.368 
  Commercial Insurance 1.43 0.90 2.27 0.130 1.54 0.86 2.75 0.144 
  Self-pay 1.98 0.76 5.15 0.160 2.41 0.85 6.86 0.098 
  Other/Unknown 2.35 0.81 6.86 0.118 2.81 0.87 9.11 0.084 
*Other: includes emergency/urgent care, inpatient care. 
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ANA. We found 5 cases (2.2% of negative ANA with 
subserologies ordered) in which an individual had a 
consistently negative ANA and at least one positive 
subserology. Of these cases, SSA and Scl-70 were the most 
likely subserologies to return as positive. The discrepancy 
between the negative ANA and positive serologies may be 
explained by the screening technique utilized by our clinical 
laboratory—the initial screen performed by ELISA and 
confirmed by IFA. Previous studies have indicated that 
screening with ELISA, while much cheaper and quicker, may 
not detect all positive ANAs found by IFA [14]. The Yazdany 
et al. paper [1] acknowledges the possibility of a positive SSA 
in the setting of a negative ANA, but Scl-70 positivity in the 
setting of a negative ANA is something that should be further 
explored. Additionally, we cannot speak to the subserologies 
of those individuals who had a negative ANA and no further 
testing was done. An important limitation of our paper is that 
the initial ANA screen is performed by ELISA and then 
confirmed by IFA. As discussed above, this excludes those 
individuals who have a negative ANA by ELISA but may 
have a positive ANA by IFA [14]. Other limitations of our 
study include the retrospective chart review nature, which is 
subject to channeling bias—i.e. only those individuals that the 
clinician had a suspicion of autoimmune disease were tested 
for ANA or further tested for subserologies. Therefore, we are 
unable to comment on the rates of positive or negative ANA 
and subserologies of the general population. Additionally, as is 
seen in retrospective studies, our study was based on clinically 
available data, which are subject to the clinical changes of data 
quality that occur over time. 
 Strengths of our study include the seven years of data 
accumulated, the large number of ANA performed, and the 
setting of the study in a safety-net hospital setting where cost 
is a daily concern. Additionally, our study reflects real-life 
clinical practice. 
CONCLUSION 
 In summary, we feel that the ACR’s Top 5 recommendation 
to not test ANA subserologies without a positive ANA and 
clinical suspicion of immune-mediated disease to be a valid 
recommendation. Only rarely did we find a patient who had a 
negative ANA and a positive subserology. In examining the 
ordering patterns of our clinicians at Denver Health, we did not 
see frank misuse of ANA testing. We did find that subspecialists 
and those involved in care in emergency/urgent/inpatient 
settings were more likely to concurrently order ANA and 
subserologies, however, clinical circumstances may have 
necessitated this approach in some cases. Future studies should 
examine other clinical settings where arthritis panels and/or 
ANA reflex testing are offered, or in settings where resources 
are not as closely guarded. Additional future studies also include 
a cost-analysis of the individual laboratory approach and 
sensitivity and specificity of ELISA vs IFA for predicting ANA 
subserologies in our population. Examining variation in 
utilization across health systems with different payment models 
is another important next step. 
LIST OF ABBREVIATIONS 
ACR = American college of rheumatology 
ANA = Antinuclear antibody 
ELISA = Enzyme-linked immunosorbent assay 
IFA = Indirect fluorescent assay 
SLE = Systemic lupus erythematosus 
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APPENDIX 
Table A1. Consistently negative ANA, positive subserologies case details. 
 
Age Gender # Neg ANA Pos Subserologies Neg Subserologies Manifestations Diagnosis Outcome 
34 F 2 SSA, RNP dsDNA, Sm, SSB leukopenia, anemia, Raynaud's, arthralgias SLE, FM placed on HCQ 
64 F 1 Scl-70 cent, Jo-1 Raynaud's, arthralgias, NSIP 
concomitant stage III 
NSCLC; possible 
paraneoplastic process 
died due to ARDS and 
sepsis 
19 F 2 SSA 
 
arthralgias, fatigue SLE,  FM placed on HCQ 
38 F 6 dsDNA cent Raynaud's, alopecia, livedo possible SLE 
placed on HCQ, lost 
to follow up 
31 F 2 Scl-70 SSA, SSB, Sm Raynaud's Raynaud's trial of HCQ not effective 
ANA: antinuclear antibody; Pos: positive; Neg: negative; dsDNA: double stranded DNA; cent: centromere; SLE: systemic lupus erythematosus; FM: fibromyalgia; HCQ: 
hydroxychloroquine; NSIP: non-specific interstitial pneumonia; NSCLC: non-small cell lung cancer; ARDS: acute respiratory distress syndrome. 
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